CD274 and neoplasm: We then performed immunohistochemical labelling on specimens from 43 glioblastoma patients with de-novo and recurrent glioblastoma to validate the presence of CD274+ astrocytes in the tumor environment, as well as GFAP and marker genes of various myeloid cell types.